Why Is Canopy Growth Stock up 8% in the Last Week?

Canopy Growth stock remains a high-risk bet, despite its 60% decline in 2022.

| More on:
Cannabis stocks have fallen.

Shares of Canadian cannabis giant Canopy Growth (TSX:WEED)(NYSE:CGC) have gained close to 8% in the last five trading sessions. The marijuana stock gained momentum, despite an analyst downgrade, as investment bank BofA downgraded WEED to “underperform” from “neutral.”

Despite the recent uptick, Canopy Growth stock has lost almost 60% in market value year to date and is down 83% from all-time highs. Let’s see if Canopy Growth is a good contrarian buy for long-term investors at current levels.

Canopy Growth wrestling with tepid revenue growth

Similar to most other cannabis companies operating in Canada, Canopy Growth is also grappling with multiple structural issues. Investors were initially optimistic about the industry’s increasing addressable market after pot was legalized for recreational use at the federal level in Canada.

However, as marijuana is a highly regulated industry, the slow rollout of retail stores in major provinces impacted top-line growth for Canopy Growth and peers. Further, the rising number of cannabis producers as well as competition from a thriving black market resulted in a price war, which negatively impacted profit margins negatively in the last few years.

These factors resulted in rising inventory levels and million-dollar write-downs for Canopy Growth. As a result, the company has missed its EBITDA targets several times, wiping out investor confidence in the process.

In the fiscal second quarter of 2022 that ended in September, Canopy Growth’s net sales fell 3% year over year to $131 million. Canopy’s management claimed that recreational sales were down 4% year over year at $58 million in Q2 due to supply chain constraints. It reported an EBITDA loss of $163 million significantly wider than its year-ago loss of $85 million.

What’s next for WEED stock investors?

Canopy Growth is well poised to expand its presence south of the border, especially if cannabis is legalized at the federal level in the United States. In fact, Canopy Growth has agreements to acquire Colorado-based Wana Brands and hemp company Acreage Holdings, upon federal legalization.

Despite high cash-burn rates, Canopy Growth enjoys financial flexibility given the 38.6% stake of Constellation Brands. Canopy Growth ended Q2 with a cash balance of $2 billion, providing enough leeway to improve its profit margins. The marijuana heavyweight expects to report a positive adjusted EBITDA by end of fiscal 2022, which might be an ambitious target considering the losses reported in its most recent quarter.

Analysts tracking WEED stock expect sales in fiscal 2022 to grow by just 5.3% to $575 million. Its revenue might then rise by 30% to $750 million in fiscal 2023. Comparatively, its net losses are forecast to narrow from $4.69 per share in fiscal 2021 to $0.71 in fiscal 2023.

Canopy Growth is trading at a market cap of $4.93 billion, valuing the stock at a forward price-to-2022 sales multiple of eight times, which is steep for a company wrestling with a string of issues. Bay Street expects WEED stock to gain by over 20% in 2022. Canopy Growth is a high-risk investment in a market that is overvalued and heading for a correction.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Brands.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Down 99% From All-Time Highs, Is Canopy Growth Stock a Good Buy Right Now?

Canopy Growth stock is a high-risk investment due to its negative profit margins and challenging liquidity position.

Read more »

Marijuana plant and cannabis oil bottles isolated
Stocks for Beginners

Aurora Cannabis’ Reverse Stock Split: Is the Stock a Buy Today?

Cannabis stock Aurora (TSX:ACB) is consolidating shares once again, but what does this mean for investors?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Where Will Cannabis Stocks Be in 10 Years?

Cannabis stocks could see a huge shift upwards should marijuana be rescheduled in the U.S., but you can still buy…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Forget Canopy Growth: 1 Cannabis Stock With Far Less Risk

Cannabis stocks like Canopy Growth (TSX:WEED) haven't done well for quite some time, yet this one deserves a major boost!

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Canopy Growth Stock Worth Buying?

Canopy Growth stock (TSX:WEED) made a big move to consolidate its shares, but will this help the company move forward?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Corp: Will it Ever Be a Buy?

Canopy Growth Corp (TSX:WEED) keeps going lower. Will it ever find a bottom?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks a Good Buy in November 2023?

Cannabis stocks have slumped a long way down in the last few years, so is November the time to get…

Read more »

A cannabis plant grows.
Cannabis Stocks

2 Top Cannabis Stocks to Buy on the TSX Today

Two cannabis stocks are the top picks as the market moves toward consolidation and stability.

Read more »